Regulation of morphogenesis in C. albicans

白色念珠菌形态发生的调控

基本信息

  • 批准号:
    8704377
  • 负责人:
  • 金额:
    $ 39.01万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-02-01 至 2016-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Lethal systemic infections caused by Candida albicans, the most common human fungal pathogen, are on the rise as new medical treatments and an aging population are increasing the pool of susceptible individuals. There is an urgent need to improve the therapeutic management of this escalating problem since current diagnostic procedures and antifungal drugs have limited effectiveness. The pathogenic effects of C. albicans are caused by its ability to grow in the host and disseminate to internal organs. Central to these processes is the plasma membrane. This essential barrier mediates secretion of virulence factors, morphogenesis, cell wall synthesis, and interfaces with the extracellular environment. The importance of the plasma membrane for virulence is underscored by the fact that it is directly or indirectly the target of the most effective antifungal drugs. Recent studies revealed that fungal plasma membranes are composed of discrete subdomains whose function in virulence and drug action is not known. Therefore, the Specific Aims are focused on the newly discovered plasma membrane subdomains called MCC/eisosomes. They consist of integral membrane proteins (MCC portion) and adjacent peripheral membrane proteins (eisosome). These unique domains are distinct from lipid rafts in that they are stable 300 nm-sized punctate patches that are associated with membrane invaginations. Our hypothesis is that MCC/eisosomes are essential for proper plasma membrane function and that their analysis will provide new paradigms for plasma membrane organization and the mechanisms of pathogenesis. In support of this, preliminary studies demonstrate that the MCC protein Sur7 is broadly important for morphogenesis, cell wall integrity, invasive growth, and virulence. Another key phenotype is that sur7¿ cells are >1,000-fold sensitive to copper, which correlates with decreased growth in macrophage phagosomes that are enriched in copper. The major goals are to identify the important proteins in these domains (Aim 1), to determine how the assembly and disassembly of MCC/eisosomes is regulated and can be perturbed by drugs (Aim 2), and to define the roles of MCC/eisosomes in virulence (Aim 3). The results are expected to aid development of new therapeutic approaches by identifying novel plasma membrane functions in fungal pathogenesis. Furthermore, these results will increase our understanding of current antifungal drugs and improve the prospects for more effective use.
描述(由申请人提供): 由于新的医学治疗和人口老龄化增加了易感个体的数量,由白色念珠菌(最常见的人类真菌病原体)引起的致命性全身感染呈上升趋势。有一个迫切的需要,以改善这种不断升级的问题,因为目前的诊断程序和抗真菌药物的有效性有限的治疗管理。C.白色念珠菌是由其在宿主体内生长并传播到内部器官的能力引起的。这些过程的中心是质膜。这种基本屏障介导毒力因子的分泌、形态发生、细胞壁合成以及与细胞外环境的界面。质膜对于毒力的重要性被以下事实所强调,即它是最有效的抗真菌药物的直接或间接靶点。最近的研究 揭示了真菌质膜由离散的亚结构域组成,其在毒力和药物作用中的功能尚不清楚。因此,特定目标集中在新发现的质膜亚结构域,称为MCC/eisosomes。它们由整合膜蛋白(MCC部分)和邻近的外周膜蛋白(eisosome)组成。这些独特的结构域不同于脂筏,因为它们是与膜内陷相关的稳定的300 nm大小的点状斑块。我们的假设是,MCC/eisosomes是必要的适当的质膜功能,他们的分析将提供新的范式质膜组织和发病机制。初步研究表明,MCC蛋白Sur 7对形态发生、细胞壁完整性、侵入性生长和毒力具有广泛的重要性。另一个关键的表型是sur 7?细胞对铜的敏感性超过1,000倍,这与富含铜的巨噬细胞吞噬体的生长减少有关。主要目标是鉴定这些结构域中的重要蛋白质(目标1),确定MCC/eisosomes的组装和拆卸如何受到药物的调节和干扰(目标2),并确定MCC/eisosomes在毒力中的作用(目标3)。这些结果有望通过鉴定真菌发病机制中新的质膜功能来帮助开发新的治疗方法。此外,这些结果将增加我们对当前抗真菌药物的了解,并改善更有效使用的前景。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

James B Konopka其他文献

James B Konopka的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('James B Konopka', 18)}}的其他基金

Signal pathways controlling the bud to hypha transition
控制芽到菌丝转变的信号通路
  • 批准号:
    9912167
  • 财政年份:
    2015
  • 资助金额:
    $ 39.01万
  • 项目类别:
Signal pathways controlling the bud to hypha transition
控制芽到菌丝转变的信号通路
  • 批准号:
    10406353
  • 财政年份:
    2015
  • 资助金额:
    $ 39.01万
  • 项目类别:
C. albicans invasive growth promotes oropharyngeal infections
白色念珠菌侵入性生长促进口咽部感染
  • 批准号:
    9014539
  • 财政年份:
    2015
  • 资助金额:
    $ 39.01万
  • 项目类别:
Signal pathways controlling the bud to hypha transition
控制芽到菌丝转变的信号通路
  • 批准号:
    9752694
  • 财政年份:
    2015
  • 资助金额:
    $ 39.01万
  • 项目类别:
N-acetylglucosamine signaling in fungi
真菌中的 N-乙酰氨基葡萄糖信号传导
  • 批准号:
    8240116
  • 财政年份:
    2009
  • 资助金额:
    $ 39.01万
  • 项目类别:
N-acetylglucosamine signaling in fungi
真菌中的 N-乙酰氨基葡萄糖信号传导
  • 批准号:
    8037634
  • 财政年份:
    2009
  • 资助金额:
    $ 39.01万
  • 项目类别:
N-acetylglucosamine signaling in fungi
真菌中的 N-乙酰氨基葡萄糖信号传导
  • 批准号:
    7772269
  • 财政年份:
    2009
  • 资助金额:
    $ 39.01万
  • 项目类别:
MEMBRANE PROTEIN TWO-HYBRID SCREEN
膜蛋白二杂交筛选
  • 批准号:
    6979555
  • 财政年份:
    2004
  • 资助金额:
    $ 39.01万
  • 项目类别:
Regulation of morphogenesis in C. albicans
白色念珠菌形态发生的调控
  • 批准号:
    9312992
  • 财政年份:
    2001
  • 资助金额:
    $ 39.01万
  • 项目类别:
Regulation of Morphogenesis in C. albicans
白色念珠菌形态发生的调控
  • 批准号:
    6330928
  • 财政年份:
    2001
  • 资助金额:
    $ 39.01万
  • 项目类别:

相似海外基金

有機分子触媒を用いたAmphotericin Bの合成研究
有机分子催化剂合成两性霉素B的研究
  • 批准号:
    24K17671
  • 财政年份:
    2024
  • 资助金额:
    $ 39.01万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
EnLAmB - Enabling global access to affordable generic liposomal amphotericin B injectable formulations via advanced manufacturing technology
EnLAmB - 通过先进的制造技术,使全球能够获得负担得起的通用脂质体两性霉素 B 注射制剂
  • 批准号:
    MR/X014010/1
  • 财政年份:
    2023
  • 资助金额:
    $ 39.01万
  • 项目类别:
    Research Grant
Encochleated Oral Amphotericin for HIV-related Cryptococcal Meningitis Trial: Phase 3 Trial
包埋口服两性霉素治疗 HIV 相关隐球菌性脑膜炎试验:3 期试验
  • 批准号:
    10619788
  • 财政年份:
    2023
  • 资助金额:
    $ 39.01万
  • 项目类别:
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
  • 批准号:
    559052-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 39.01万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Study on naturally-occurring peptides potentiating amphotericin B activity
天然存在的肽增强两性霉素 B 活性的研究
  • 批准号:
    22K05333
  • 财政年份:
    2022
  • 资助金额:
    $ 39.01万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Integrating genome-wide association study, quantitative trait loci mapping and transcriptome sequencing to identify genes associated with amphotericin B resistance in Aspergillus fumigatus
整合全基因组关联研究、数量性状基因座作图和转录组测序,鉴定与烟曲霉两性霉素 B 耐药性相关的基因
  • 批准号:
    559052-2021
  • 财政年份:
    2021
  • 资助金额:
    $ 39.01万
  • 项目类别:
    Alexander Graham Bell Canada Graduate Scholarships - Doctoral
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
  • 批准号:
    10024667
  • 财政年份:
    2020
  • 资助金额:
    $ 39.01万
  • 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
  • 批准号:
    9909193
  • 财政年份:
    2020
  • 资助金额:
    $ 39.01万
  • 项目类别:
Amphotericin B Restoration of Anion Secretion in Cystic Fibrosis Airways
两性霉素 B 恢复囊性纤维化气道阴离子分泌
  • 批准号:
    10248529
  • 财政年份:
    2020
  • 资助金额:
    $ 39.01万
  • 项目类别:
Development of NH101: A Simple and Efficient Outpatient Dry Powder Amphotericin B-DryNeb(dry powder nebulizer) for Treatment of Susceptible and Multidrug Resistant Aspergillus/ Fungal Infections
NH101的开发:一种简单高效的门诊干粉两性霉素B-DryNeb(干粉雾化器),用于治疗敏感和多重耐药曲霉菌/真菌感染
  • 批准号:
    10484014
  • 财政年份:
    2020
  • 资助金额:
    $ 39.01万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了